<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953420</url>
  </required_header>
  <id_info>
    <org_study_id>25145-CADEN</org_study_id>
    <secondary_id>CADEN</secondary_id>
    <nct_id>NCT00953420</nct_id>
  </id_info>
  <brief_title>Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes</brief_title>
  <acronym>CADEN</acronym>
  <official_title>Phase II Study of Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes in Patients With Refractory/Relapsed EBV-positive Nasopharyngeal Carcinoma(CADEN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients have a type of cancer called nasopharyngeal carcinoma (NPC) that has either come&#xD;
      back or not gone away after the best known standard treatments.&#xD;
&#xD;
      Most patients that respond to chemotherapy once their NPC tumors have come back have been&#xD;
      treated with a platinum-based medication like cisplatin. However, since many patients are&#xD;
      given cisplatin during their initial treatment for NPC, in this study, they will be treated&#xD;
      with another platinum-based chemotherapy medicine that has been used in patients with NPC&#xD;
      called carboplatin. In this study, carboplatin will be used in combination with another drug&#xD;
      called docetaxel. Other studies in patients with advanced head and neck cancer have shown&#xD;
      that docetaxel can cause tumors to respond better and allow patients to survive longer when&#xD;
      added to the standard treatments for those diseases.&#xD;
&#xD;
      Some patients with NPC show evidence of infection with the virus that causes infectious&#xD;
      mononucleosis, known as the Epstein Barr virus (EBV), before or at the time of their cancer&#xD;
      diagnosis. EBV is found in the cancer cells of almost all patients with advanced stage&#xD;
      disease, suggesting that it may play a role in causing NPC. Previously, patients have been&#xD;
      treated with high-risk NPC using EBV-specific cytotoxic T cells. These cells are grown in the&#xD;
      laboratory and taught to recognize and attack EBV infected cells. In the past, patients were&#xD;
      either given the cells alone or just after they had received a medication to briefly lower&#xD;
      their white blood cell count. In both cases, many patients had their tumors shrink and in&#xD;
      some cases completely disappear after being treated with these EBV-specific cytotoxic T&#xD;
      cells.&#xD;
&#xD;
      Investigators have now decided to look at how patients with NPC and their tumors respond to&#xD;
      the treatment combination of chemotherapy and EBV-CTL. Patients are being asked to&#xD;
      participate in this study since the NPC tumor is associated with EBV and has either come back&#xD;
      or not responded to standard treatment. This combination of chemotherapy and EBV-CTLs is an&#xD;
      investigational treatment not approved by the Food and Drug Administration.&#xD;
&#xD;
      The purpose of this study is to see how relapsed or refractory, EBV-associated NPC tumors&#xD;
      respond when treated with carboplatin and docetaxel followed by EBV-CTL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A blood sample will be obtained to start making the CTLs before the patient begins&#xD;
      chemotherapy. The patients EBV-specific T cells will be grown while the patient is being&#xD;
      treated with chemotherapy and given back to the patient after their chemotherapy is&#xD;
      completed.&#xD;
&#xD;
      To prepare the CTLs, 60-70 cc of blood will be taken from the patient. The amount of blood&#xD;
      collected depends on their size and weight, no more than 3 cc of blood per kg of body weight&#xD;
      will be collected at any one time.&#xD;
&#xD;
      This blood will be used to grow an EBV-infected B-cell line and then a T-cell line. B cells&#xD;
      and T cells are types of white blood cells that help fight infections in the body. After&#xD;
      growing T cells in the laboratory, these cells will be stimulated with EBV infected B cells.&#xD;
      The B cells have been treated with radiation so they cannot grow; however, they can provide&#xD;
      the stimulation that will train the T cells to recognize and kill EBV infected cells.&#xD;
&#xD;
      The generation of EBV-CTL requires the use of a special cell line, called lymphoblastoid cell&#xD;
      line, which will be made from the blood by infecting cells with EBV. Once the LCLs are made,&#xD;
      the T cells will be repeatedly stimulate with the LCLs to make EBV-CTL.&#xD;
&#xD;
      The CTLs will then be tested to make sure they kill the EBV infected cells before they are&#xD;
      given back to the patient. If the number of CTLs produced is low, investigators may need to&#xD;
      obtain additional blood samples to make these cells.&#xD;
&#xD;
      Because the patients cells are being grown in the laboratory, blood will have to be taken to&#xD;
      test for infectious viruses such as hepatitis and HIV and patients will also have to fill in&#xD;
      a questionnaire that is given to standard blood donors.&#xD;
&#xD;
      EXPECTED LENGTH OF STUDY The chemotherapy treatment portion is planned as 4 cycles of&#xD;
      chemotherapy given every 3 weeks. Up to an additional 2 cycles of chemotherapy may be given&#xD;
      if the EBV-CTL product is not available after the initial 4 cycles.&#xD;
&#xD;
      If the patient has been able to complete at least 4 cycles of chemotherapy and the EBV-CTL&#xD;
      are ready for infusion,then the cells will be given back to the patient. The infusion of the&#xD;
      T cells will last about 1 to 5 minutes after the patient has been pretreated with one dose of&#xD;
      Tylenol and Benadryl.&#xD;
&#xD;
      The patient will have another disease re-evaluation 8 weeks after the first EBV-CTL&#xD;
      injection. Based upon the patient's response to the first infusion, the patient may receive&#xD;
      extra doses of cells if they are available. These would be given every 1.5-3 months. If the&#xD;
      patient has additional injections of cells, this will require an additional disease&#xD;
      re-evaluation 8 weeks after each infusion.&#xD;
&#xD;
      To learn more about the way the EBV-CTLS are working and how long they last in the body,&#xD;
      10-60 mls of blood will be taken before and after each infusion. Up to 60 ml of blood will&#xD;
      also be drawn before each cycle of chemotherapy that occurs at Week 1, Week 4, Week 7, Week&#xD;
      10 before the T cell infusion and then at Weeks 1, 2, 4, 6 and 8 weeks after infusion, and&#xD;
      then again at the follow-up visits 5, 8, and 11-12 months after infusion. This blood will be&#xD;
      used to look at the immune response to the patient's cancer. If the patient only has one&#xD;
      EBV-CTL infusion, up to 108 teaspoons of blood will be drawn to allow for evaluation of his&#xD;
      or her response to treatment; however, the total amount of blood collected on this study will&#xD;
      depend on the total number of EBV-CTL infusions that the patient has.&#xD;
&#xD;
      The patient and his/her response to therapy will be followed for at least 1 year after&#xD;
      treatment on this study ends.&#xD;
&#xD;
      STUDY TREATMENT While the cells are being grown, the patient will be started on chemotherapy&#xD;
      in order to shrink the size and/or amount of his/her tumor.&#xD;
&#xD;
      The patient will be treated with a combination of docetaxel and carboplatin chemotherapy. The&#xD;
      chemotherapy will be given outpatient over several hours. Docetaxel can cause the body to&#xD;
      hold on to extra fluid (fluid retention). This side effect can be prevented in most people if&#xD;
      they take a small steroid dose before and after docetaxel is given. Therefore, the night&#xD;
      before and on the morning chemotherapy is to start, the patient will take a steroid called&#xD;
      dexamethasone by mouth.&#xD;
&#xD;
      Once the patient gets to clinic, he/she will be given a dose of docetaxel and then a dose of&#xD;
      carboplatin. Each of these medications will be given into the vein after an IV is placed or&#xD;
      into the central line. The patient will then take the last dose of dexamethasone before going&#xD;
      to bed that night. The patient will receive chemotherapy treatment once every 21 days as long&#xD;
      as the patient's blood counts and laboratory tests have returned to an acceptable level. The&#xD;
      patient will have a re-evaluation of his/her disease with imaging scans and laboratory tests&#xD;
      after the second round of chemotherapy. If the patient's tumor has not gotten worse and/or&#xD;
      has not had severe side effects from the chemotherapy, the patient will be treated with 2 to&#xD;
      4 additional rounds of chemotherapy while we are waiting for the EBV-CTLs to be finished.&#xD;
&#xD;
      The combination of chemotherapy agents used in this study might cause the patient's white&#xD;
      blood cells to be low. If they are low for a long period of time or the patient develop a&#xD;
      serious infection while they are low, her/she may be given an extra medication called&#xD;
      Granulocyte colony-stimulating factor (GCSF). GCSF helps to stimulate the production of white&#xD;
      blood cells. However, it is anticipated that most people on the study will not require GCSF.&#xD;
&#xD;
      Once the EBV-CTLs are ready and the patient has recovered from the last round of&#xD;
      chemotherapy, the EBV-CTL infusion will be scheduled. The CTL infusion will take place at&#xD;
      either Houston Methodist Hospital or Texas Children's Hospital. The CTL infusion takes about&#xD;
      1 to 5 minutes, but patients are typically monitored for up to 4 hours after the infusion to&#xD;
      make sure that he/she does not have a reaction to the cells.&#xD;
&#xD;
      END OF TREATMENT AND FOLLOW-UP&#xD;
&#xD;
      The patient will have a number of tests and procedures as part of follow up to treatment.&#xD;
      These tests will be used to watch for improvements in tumor size, monitor for side effects&#xD;
      from the treatment, evaluate how the T cells are working, and look for any signs that the&#xD;
      cancer has come back. The patient's will have a physical exam and standard lab tests,&#xD;
      including blood tests, and imaging studies about every 3 months during the first year after&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study is to evaluate the overall response rate for patients with advanced-stage, relapsed/refractory, EBV positive nasopharyngeal carcinoma after re-induction chemotherapy and immunotherapy.</measure>
    <time_frame>3 months</time_frame>
    <description>The overall response rate for patients with advanced-stage, relapsed/refractory, EBV positive nasopharyngeal carcinoma after re-induction chemotherapy (treatment with docetaxel and carboplatin) followed by immunotherapy with EBV-specific Cytotoxic T lymphocytes will be measured. Response rates will be estimated as the percent of patients whose best response is a CR or PR, and a 95% confidence interval will be calculated for the fraction of responses obtained.To measure the overall response rate, disease will be determined by imaging (MRI, CT, and/or PET imaging) 8 weeks after immunotherapy. In addition, per standard of care, disease re-evaluation will continue 3 months during the first year after participation and then as clinically indicated per the patient's primary oncologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to re-induction chemotherapy</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immune response by measuring EBV-DNA levels</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 60 mg/m2 IV on Day 1&#xD;
Carboplatin with target AUC of 5 (mg/ml x min) on Day 1&#xD;
Dexamethasone 5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1&#xD;
After cycle 1, subsequent cycles of chemotherapy may start once ANC &gt; 1000 and platelets &gt; 100,000 post nadir&#xD;
Up to an additional 2 cycles of chemotherapy, given per the above schedule, may be given if the EBV-specific cytotoxic T lymphocytes product is not available after the initial 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>60 mg/m2 IV on Day 1</description>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Target AUC of 5 (mg/ml x min) on Day 1</description>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1</description>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EBV-specific cytotoxic T lymphocytes</intervention_name>
    <description>1 x 10e8 cells/m2 IV over 1 to 5 min</description>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <other_name>EBV-specific cytotoxic T lymphocytes 1 x 10e8 cells/m2 IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G-CSF or Peg-GCSF</intervention_name>
    <description>If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg â‰¤ 45 kg; 6 mg for &gt; 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC &gt; 2500 cells/ul x 2 days after nadir.</description>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <other_name>Filgrastim or pegylated filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory&#xD;
             disease in whom the EBV-genome or antigens have been demonstrated in tissue biopsy&#xD;
             samples&#xD;
&#xD;
          -  Age 10 years or older&#xD;
&#xD;
          -  Life expectancy of 8 weeks or more&#xD;
&#xD;
          -  Karnofsky or Lansky score of 50 or more&#xD;
&#xD;
          -  Normal bilirubin level (per institutional standard)&#xD;
&#xD;
          -  AST and ALT 1.5 x or less upper limit of normal&#xD;
&#xD;
          -  Alk Phos level less than 2.5 x upper limit of normal&#xD;
&#xD;
          -  ANC greater than 1500 cells/ul&#xD;
&#xD;
          -  Hgb 8.0 or greater&#xD;
&#xD;
          -  Platelets 100,000 cells/ul or more&#xD;
&#xD;
          -  Creatinine 2 x or less ULN or GFR 50 ml/min/1.73 m2 or more&#xD;
&#xD;
          -  Women of child-bearing potential must take/use effective birth control while&#xD;
             participating in the study.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Due to the unknown effects of this therapy on a fetus, pregnant women will be excluded&#xD;
             from this research.&#xD;
&#xD;
          -  Prior allergic reaction to the study drugs used in this protocol or other drugs&#xD;
             formulated with polysorbate 80.&#xD;
&#xD;
          -  Known HIV positive subjects since treatment may be significantly immunosuppressive&#xD;
&#xD;
          -  Women who are breast-feeding&#xD;
&#xD;
          -  Severe intercurrent infection&#xD;
&#xD;
          -  Patients, who in the opinion of the investigator, may not be able to comply with the&#xD;
             safety monitoring requirements of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrystal U Louis, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Children's Hospital; Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <disposition_first_submitted>August 26, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>August 26, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 9, 2015</disposition_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Chrystal Louis</investigator_full_name>
    <investigator_title>Assistant Professor Pediatrics-Hem-Onc Cell &amp; Gene</investigator_title>
  </responsible_party>
  <keyword>nasopharyngeal carcinoma</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Epstein-Barr Virus</keyword>
  <keyword>T Lymphocytes</keyword>
  <keyword>EBV-CTLs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

